Lv41
420 积分 2023-06-06 加入
Antibody-drug conjugates in oncology: A spotlight on overcoming resistance
4天前
已完结
HER2 testing: evolution and update for a companion diagnostic assay
7天前
已完结
HER2-targeted therapies beyond breast cancer — an update
8天前
已完结
A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer
28天前
已完结
Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody–drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study
28天前
已完结
Is immunology doing well? A look at 100 immune‐mediated inflammatory diseases for 100 years of the Journal
1个月前
已完结
Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases
1个月前
已完结
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
1个月前
已完结
Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial
1个月前
已完结
Inflammation across tissues: can shared cell biology help design smarter trials?
1个月前
已完结
皖公网安备34019202002308
